Topvision Eye Specialist Bhd
MMYX:TOPVISN0.17
MYR
0.00
(0.00%)
ISIN
MYQ0332OO005
Return %
Stock
S&P 500
1Y
-21.43
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Kuok Siong Chong
- Sector
- Health services
- Industry
- Medical/Nursing services
- Address
- Shah Alam Malaysia
- IPO Date
- Dec 16, 2024
- Website
- tvesc.com
- Similar Companies
- Business
- Topvision Eye Specialist Berhad is a Malaysia-based healthcare company primarily engaged in the provision of comprehensive medical, surgical, and ambulatory eye care specialist services. Founded in 2010 and headquartered in Shah Alam, Selangor, Malaysia, the company operates an integrated network of ambulatory care centres offering specialized ophthalmic diagnostic, therapeutic, surgical, and optical solutions. The company operates through its healthcare subsidiaries and provides a systematic portfolio of clinical offerings: cataract surgery and lens replacement, including micro-incision phacoemulsification, monofocal, multifocal, extended depth of focus (EDOF), and toric intraocular lens (IOL) implantations, and secondary lens repositioning; refractive vision correction, comprising small incision lenticule extraction (SMILE / SMILE Pro), laser-assisted in situ keratomileusis (LASIK), photorefractive keratectomy (PRK), and implantable collamer lens (ICL) surgeries; vitreoretinal disease management, featuring vitrectomy, retinal tear repair, retinal detachment surgery, laser photocoagulation, and intravitreal anti-VEGF injections for diabetic retinopathy and age-related macular degeneration; glaucoma diagnostics and management, encompassing medical intraocular pressure management, selective laser trabeculoplasty, laser peripheral iridotomy, trabeculectomy, and glaucoma drainage implant surgery; cornea and external eye disease treatments, involving corneal cross-linking for keratoconus, pterygium excision with conjunctival autograft, and dry eye therapy; pediatric ophthalmology and strabismus management, including amblyopia correction, pediatric refraction, and squint realignment surgery; advanced ophthalmic diagnostic investigations, utilizing optical coherence tomography, digital fundus photography, computerized visual field perimetry, corneal topography, optical biometry, and pachymetry; and optical dispensing, encompassing the sale and prescription of ophthalmic pharmaceuticals, post-operative medications, corrective lenses, optical frames, and contact lenses. The company provides its services across Peninsular Malaysia with established ambulatory care centres located throughout Selangor, Kuala Lumpur, Johor, Perak, Melaka, and Negeri Sembilan. In recent developments, Topvision has advanced its strategic transfer of listing from the LEAP Market to the ACE Market of Bursa Malaysia to enhance market liquidity and support long-term capital expansion. In parallel, the company has actively expanded its ambulatory care network across Peninsular Malaysia by launching new specialized eye centres, upgrading clinical facilities with next-generation laser vision correction platforms, and expanding its subspecialty capabilities in vitreoretinal and refractive surgical care.